0000891293-22-000033.txt : 20220617 0000891293-22-000033.hdr.sgml : 20220617 20220617165744 ACCESSION NUMBER: 0000891293-22-000033 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220617 FILED AS OF DATE: 20220617 DATE AS OF CHANGE: 20220617 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KIRSKE DAVID CENTRAL INDEX KEY: 0001276750 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 221024732 MAIL ADDRESS: STREET 1: C/O CTI BIOPHARMA CORP. STREET 2: 3101 WESTERN AVE., SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 4 1 primary_doc.xml PRIMARY DOCUMENT X0306 4 2022-06-17 0 0000891293 CTI BIOPHARMA CORP CTIC 0001276750 KIRSKE DAVID CTI BIOPHARMA CORP. 3101 WESTERN AVE., SUITE 800 SEATTLE WA 98121 0 1 0 0 EVP, Chief Financial Officer common stock 2022-06-17 4 M 0 10000 1 A 17397 D common stock 2022-06-17 4 S 0 10000 6 D 7397 D common stock 2022-06-17 4 M 0 50000 3.3 A 57397 D common stock 2022-06-17 4 S 0 50000 6.2501 D 7397 D Non-Qualified Stock Option (right to buy) 1 2022-06-17 4 M 0 10000 0 D 2030-03-11 Common Stock 10000 340000 D Non-Qualified Stock Option (right to buy) 3.3 2022-06-17 4 M 0 50000 0 D 2031-03-10 Common Stock 50000 150000 D This sale was effected pursuant to a 10b5-1 sales plan adopted by the reporting person. One sixth of the shares underlying the option vested on 9/11/2020 and semi-annually thereafter until all the underlying shares will be fully vested on 3/11/2023. One sixth of the shares underlying the option vested on 9/10/2021 and semi-annually thereafter until all the underlying shares will be fully vested on 3/10/2024. David Kirske 2022-06-17